These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24731273)

  • 1. Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein.
    Tai VW; Garrido D; Price DJ; Maynard A; Pouliot JJ; Xiong Z; Seal JW; Creech KL; Kryn LH; Baughman TM; Peat AJ
    Bioorg Med Chem Lett; 2014 May; 24(10):2288-94. PubMed ID: 24731273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.
    Zhang X; Zhang N; Chen G; Turpoff A; Ren H; Takasugi J; Morrill C; Zhu J; Li C; Lennox W; Paget S; Liu Y; Almstead N; Njoroge FG; Gu Z; Komatsu T; Clausen V; Espiritu C; Graci J; Colacino J; Lahser F; Risher N; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3947-53. PubMed ID: 23683597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.
    Pouliot JJ; Thomson M; Xie M; Horton J; Johnson J; Krull D; Mathis A; Morikawa Y; Parks D; Peterson R; Shimada T; Thomas E; Vamathevan J; Van Horn S; Xiong Z; Hamatake R; Peat AJ
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6539-50. PubMed ID: 26259798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B.
    Zhang N; Turpoff A; Zhang X; Huang S; Liu Y; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Pichardo J; Colacino J; Lahser F; Ingravallo P; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2016 Jan; 26(2):594-601. PubMed ID: 26652483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C replication inhibitors that target the viral NS4B protein.
    Miller JF; Chong PY; Shotwell JB; Catalano JG; Tai VW; Fang J; Banka AL; Roberts CD; Youngman M; Zhang H; Xiong Z; Mathis A; Pouliot JJ; Hamatake RK; Price DJ; Seal JW; Stroup LL; Creech KL; Carballo LH; Todd D; Spaltenstein A; Furst S; Hong Z; Peat AJ
    J Med Chem; 2014 Mar; 57(5):2107-20. PubMed ID: 23544424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction networks of hepatitis C virus NS4B: implications for antiviral therapy.
    Li S; Yu X; Guo Y; Kong L
    Cell Microbiol; 2012 Jul; 14(7):994-1002. PubMed ID: 22329740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of novel carbocyclic versions of 2'-spirocyclopropyl ribonucleosides as potent anti-HCV agents.
    Oh CH; Kim E; Hong JH
    Nucleosides Nucleotides Nucleic Acids; 2011 Jun; 30(6):423-39. PubMed ID: 21780908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates.
    Rajyaguru S; Yang H; Martin R; Miller MD; Mo H
    Antiviral Res; 2013 Nov; 100(2):328-36. PubMed ID: 24013002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents.
    Wang NY; Xu Y; Zuo WQ; Xiao KJ; Liu L; Zeng XX; You XY; Zhang LD; Gao C; Liu ZH; Ye TH; Xia Y; Xiong Y; Song XJ; Lei Q; Peng CT; Tang H; Yang SY; Wei YQ; Yu LT
    J Med Chem; 2015 Mar; 58(6):2764-78. PubMed ID: 25710739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase.
    Bassetto M; Leyssen P; Neyts J; Yerukhimovich MM; Frick DN; Courtney-Smith M; Brancale A
    Eur J Med Chem; 2017 Jan; 125():1115-1131. PubMed ID: 27810598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Drug Discovery for Anti-hepatitis C Virus Targeting NS4B.
    Wang Z; Chen X; Wu C; Xu H; Liu H
    Curr Top Med Chem; 2016; 16(12):1362-71. PubMed ID: 26585935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Synthesis of a Spirocyclic Macrocyclic Protease Inhibitor for the Treatment of Hepatitis C.
    Chung CK; Cleator E; Dumas AM; Hicks JD; Humphrey GR; Maligres PE; Nolting AF; Rivera N; Ruck RT; Shevlin M
    Org Lett; 2016 Mar; 18(6):1394-7. PubMed ID: 26950496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6-(Azaindol-2-yl)pyridine-3-sulfonamides as potent and selective inhibitors targeting hepatitis C virus NS4B.
    Chen G; Ren H; Zhang N; Lennox W; Turpoff A; Paget S; Li C; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Colacino J; Lahser F; Zhao X; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2015 Feb; 25(4):781-6. PubMed ID: 25613678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.
    Kazmierski WM; Maynard A; Duan M; Baskaran S; Botyanszki J; Crosby R; Dickerson S; Tallant M; Grimes R; Hamatake R; Leivers M; Roberts CD; Walker J
    J Med Chem; 2014 Mar; 57(5):2058-73. PubMed ID: 24568313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and Structure-Resistance Relationship Study of New Thieno[2,3-
    Xiao KJ; Zuo WQ; Xu Y; Tao X; Yu LT; Wang NY
    Pharmazie; 2019 Jun; 74(6):321-325. PubMed ID: 31138367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and structure-activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors.
    Wang NY; Zuo WQ; Xu Y; Gao C; Zeng XX; Zhang LD; You XY; Peng CT; Shen Y; Yang SY; Wei YQ; Yu LT
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1581-8. PubMed ID: 24529869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network based analysis of hepatitis C virus core and NS4B protein interactions.
    Tripathi LP; Kataoka C; Taguwa S; Moriishi K; Mori Y; Matsuura Y; Mizuguchi K
    Mol Biosyst; 2010 Dec; 6(12):2539-53. PubMed ID: 20953506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors.
    Vijgen L; Verbeeck J; Van Kerckhove B; Berke JM; Koletzki D; Fanning G; Lenz O
    Methods Mol Biol; 2013; 1030():105-17. PubMed ID: 23821263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.